Free accessResearch articleFirst published online 2009-06
The TT Genotype of the C677T Polymorphism in the Methylentetrahydrofolate Reductase as a Risk Factor in Thrombotic Microangiopathies: Results From a Pilot Study
In this study, we assessed the potential role of the TT genotype of the gene of the methylenetetrahydrofolate reductase for the manifestation of thrombotic microangiopathies, enrolling 40 affected patients (mean age [± standard deviation] 35 ± 11 years). As a result, the methylenetetrahydrofolate reductase 677TT genotype was more prevalent in patients with thrombotic microangiopathies compared with controls (adjusted odds ratio = 2.58, 95% confidence interval = 1.2-5.7, P = .018), particularly in those suffering from the hemolytic uremic syndrome. A hemolytic more severe clinical course of thrombotic microangiopathies in carriers of the methylenetetrahydrofolate reductase 677TT genotype was not observed. In summary, our findings suggest a significant influence of the methylenetetrahydrofolate reductase genotype on the manifestation of thrombotic microangiopathies. The 677 TT genotype of this polymorphism appears to be a risk factor for manifestation of these rare thrombotic disorders, possibly explained by endothelial activation and increased oxidative stress.
Ray JG, Shmorgun D., Chan WSCommon C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb. 2002;32:51-58.
2.
Caso V., Paciaroni M.MTHFR 677 TT genotype and hyperhomocysteinaemia: an underestimated risk TANDEM for patients with stroke. J Neurol Neurosurg Psychiatry. 2006;77:1103.
3.
Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinaemia, methylentetrahydrofolate reductase polymorphism and risk of coronary heart disease. Ann Clin Biochem. 2006;43:200-206.
4.
Abu-Zamzam AMHomocysteine as a risk factor for peripheral vascular disease. In: Robinson K, ed. Homocysteine and vascular disease. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2000:135-149.
5.
Kupferminc MJ , Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
6.
Moake JLThrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
7.
Franchini M., Zaffanelli M., Veneri D.Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Res. 2006;118:177-184.
8.
George JN, Vesely SK, Terrell DRThe Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41:60-67.
9.
Krieg S., Studt JD, Sulzer I., Lammle B., Hovinga JAIs factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost. 2005;94:1186-1189.
10.
Raife T., Lentz S., Atkinson B., Vesely S., Hessner M.Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood. 2002;99: 437-442.
11.
Sucker C., Hetzel GR, Farokhzad F., et al. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies-a pilot study. Nephrol Dial Transplant. 2007;22:1347-1350.
12.
Rose M., Eldor A.High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med. 1987;83:437-444.
13.
Von Ahsen N. , Schutz E., Armstrong VW, Oellerich M.Rapid detection of prothrombotic mutations of pro-thrombin (G20210A), factor V (G1691A), and methylenetetrahydrofolate reductase (C677T) by real-time fluorescence PCR with the LightCycler. Clin Chem. 1999;45:694-696.
14.
Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylentetrahydrofolate reductase. Nat Genet . 1995; 10:111-113.
15.
Harmon DL, Woodside JV, Yarnell JW, et al. The common `thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM. 1996;89:571-577.
16.
Finkelstein JDPathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 2000;26:219-225.
17.
Rozen R.Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med. 1996;19:171-178.
18.
Malinow MR, Nieto FJ, Szklo M., Chambless LE, Bond G.Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation. 1993;87:1107-1113.
19.
Harker LA, Harlan JM, Ross R.Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 1983;53:731-739.
20.
Di Minno G. , Davi G., Margaglione M., et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92: 1400-1406.
21.
Mc Cully KS , Vezeridis MPHistopathological effects of homocysteine thiolactone on epithelial and stromal tissues. Exp Mol Pathol . 1989;51:159-170.
22.
Olszewski AJ , Mc Cully KSHomocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med. 1993;14:683-693.
23.
Duell PB, Malinow MRHomocysteine as a risk factor for coronary artery disease. In: Robinson K, ed. Homocysteine and vascular disease. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2000:173-202.
24.
Nygard O., Nordrehaug JE, Refsum H., Ueland PM, Farstad M., Vollset SEPlasma homocysteine levels and mortality in patients with coronary heart disease . N Engl J Med. 1997;337:230-236.
25.
Perry IJHomocysteine as a risk factor for cerebrovascular disease and stroke. In: Robinson K, ed. Homocysteine and vascular disease. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2000:151-172.
26.
Prengler M. , Sturt N., Krywawych S., et al. Homozygous thermolabile variant of the methylentetrahydrofolate reductase gene: a potential risk factor for hyperhomocysteinemia, CVD and stroke in childhood. Dev Med Child Neurol. 2001;43:220.
27.
Bolander-Gouaille C.Focus on Homocysteine and the Vitamins Involved in its Metabolism. 2nd ed. Paris , France: Springer Verlag; 2001.
28.
Andria G., Fowler B., Sebastio G.Disorders of sulfur amino acid metabolism. In: Fernandes J, Saudubray JM, van den Berghe G, eds. Inborn metabolic diseases . 3rd ed. New York, NY: Springer; 2000.
29.
Araki A., Hosoi T., Orimo H., Ito H.Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism. 2005;54:809-814.
30.
Dedoussis GV , Panagiotakos DB, Pitsavos C., et al. An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease. Int J Cardiol. 2005;100:409-414.
31.
Stanger O., Herrmann W., Pietrzik K., et al. Consensus paper on the rational clinical use of homocysteine, folic acid and b-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003 ;41:1392-1403.
32.
Armada E., Perez C., Otero A., et al. Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients. Clin Nephrol. 2003 ;60:168-175.
